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Background: Stimulation of the primary motor cortex (M1) has been shown to reduce the pain of neuropathy in
multiple studies. There are several methods of stimulation both invasive and non-invasive. Recent work by this
laboratory has seen that 40% of a sample of chronic neuropathic pain patients responded positively to non-invasive
repetitive transcranial magnetic stimulation (rTMS) to the motor cortex with a reduction in pain levels by at least 20%.
The effect however is short lived and multiple return visits are necessary to maintain this response. Transcranial direct
current stimulation (tDCS) offers a more mobile method of motor cortex stimulation and is similarly non-invasive.
The protocol described is designed to assess the analgesic effect of a home-based tDCS treatment device on
chronic neuropathic pain in both responders and non-responders to previous TMS treatment.
Methods/design: This article reports the protocol for a randomised, sham-controlled, double-blinded crossover
study in which patients with chronic neuropathic pain (n = 24) will receive anodal, cathodal and sham tDCS over
M1. All patients will have previously completed a study of rTMS of the motor cortex and have been designated
as responders or non-responders to this modality.
Patients receive all three tDCS stimulation types by self-administration. We assess the effect on pain scores
[numerical rating scale (NRS)], self reported health status (Short Form-36 Health Survey) and anxiety/depression
(Hospital Anxiety and Depression Scale). A linear mixed model with fixed effects will analyse changes in pain
scores from pre- to post- interventions. Analysis will be carried out on an intention-to-treat basis. A proportion
analysis will also be carried out with patients separated into either responders or non-responders to previous TMS.
Safety will be assessed throughout the study by monitoring of adverse events.
Discussion: The result of this trial will assess the efficacy of self-administered tDCS of the motor cortex in the treatment
of chronic neuropathic pain and also provide insight into whether a potential differential effect is seen in patients that
have previously been shown to be either responsive or non-responsive to rTMS over the same area.
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Stimulation of the primary motor cortex (M1) of the
brain was first shown to reduce central pain in patients
by Tsubokawa et al. [1] using implanted electrodes in
the epidural space around the brain. More recently, non-
invasive methods of cortical stimulation have been tested
such as repetitive transcranial magnetic stimulation (rTMS)
and transcranial direct current stimulation (tDCS) [2].
Previous research in our laboratory has shown that ap-
proximately 40% of chronic pain patients obtained at least
20% improvement in pain scores following high-frequency
rTMS of the M1 motor cortex [3] lasting for approximately
2 weeks consistent with other rTMS studies [4,5]. The ef-
fect seems to be maintained as long as rTMS sessions con-
tinue, but this requires frequent attendances by patients.
The proposed study is based on the hope that tDCS could
offer an alternative method for cortical stimulation in this
group of patients. As portable tDCS devices have become
available, patients/carers can be trained in its application
and patients may use these at home without the need for
regular visits to our laboratory. If proven sufficiently effect-
ive, tDCS could offer an economical and convenient way of
delivering cortical stimulation for pain relief.
tDCS involves the application of a low-amplitude con-
stant electric current to the scalp, a proportion of which
enters the skull to affect cortical activity in the brain. It
does not directly induce action potentials in neurons but
rather alters the membrane potential and thus influences
the excitability of these cells [6,7]. Typically it is applied
via two electrodes, an anode and a cathode, with the
current travelling from anode to cathode. The polarity
however can be changed by reversing the electrode pos-
ition. Anodal stimulation of the scalp overlying the cortex
results in increased excitability of this cortical area whilst
cathodal stimulation has the opposite effect [8].
It has been shown to be effective in the treatment of
various conditions including motor function recovery
following stroke, reduced epileptiform discharges in epi-
lepsy, mood elevation in depression and improvement of
motor function in Parkinson’s disease [9-12].
Several studies have also shown it reduces the percep-
tion of acute pain [13,14] and experimentally induced
acute pain in healthy volunteers [15,16] and in post-
operative pain [17]. In chronic pain conditions that are re-
fractory to medical treatment, anodal tDCS stimulation
has been shown to reduce pain (at least in the short term)
in fibromyalgia [18,19], pelvic pain [20], cancer pain [21]
and spinal cord injury [22,23], although in spinal cord in-
jury pain recent studies have not replicated positive results
[24]. In a crossover trial where volunteers were exposed to
both anodal and sham tDCS over the M1 motor cortex
hand area, Antal et al. [25] demonstrated a reduction in
chronic pain scores and a normalisation of intra-cortical
inhibition. These effects persist for several weeks aftertreatment and may reflect long-term plastic changes at
neuronal synapses [26-29].
tDCS of the motor cortex also influences the activity
of areas distant to the site of stimulation and this is
probably achieved through inter-neuronal connections
between these sites [30]. This is supported by imaging
studies in humans, indicating that cortical stimulation
reduces pain by modulating activity in networks of brain
areas involved in pain processing, such as the thalamus
or by facilitating descending pain inhibitory mechanisms
[31-34]. Side effects are uncommon and relatively minor
(mostly headache, itch and skin redness) and it is con-
sidered a very safe form of treatment with a few contra-
indications [35-37].
Aims
The main aim of this study will be to determine the effi-
cacy of home-based tDCS treatment in two chronic
neuropathic pain patient populations: responders and
non-responders to rTMS. The hypothesis is that those
patients who have previously responded to rTMS will
also respond to tDCS while non-responders may not. To
test this hypothesis TMS responders will be subjected to
three different types of tDCS: anodal, cathodal and sham
tDCS. In addition, there remains a possibility that tDCS
may show efficacy even in those patients who previously
have not responded to rTMS. Therefore, non-responders
will be subjected to the same three modes of stimulation
as responders.
Methods/Design
Ethical approval for this study was granted from the
National Research Ethics Committee REC reference 12/
EE/0315.
Patient selection
Patients will be selected based on response to previous
treatment with rTMS for chronic pain, i.e., all subjects,
both responders and non-responders from previous
rTMS studies, will be invited to participate. All subjects
shall be informed of the purpose of the experiment and
written consent to enter the study will be obtained prior
to entering the study by the principal investigator.
Inclusion criteria
Inclusion criteria include (1) age between 18–85 years;
(2) stable analgesic medication for the prior month; (3)
mean pain levels ≥4 out 10 on VAS for pain during the
1-week run-in phase, based on patient diary; (4) willing-
ness to take part; (5) ability to consent; (6) previously had
a minimum of five sessions of TMS for pain, and can be
named as a “responder” or “non-responder” where the re-
sponder reports a weekly average pain reduction of 20%
on an NRS of 0–10, following five rTMS sessions.
O’Neill et al. Trials  (2015) 16:186 Page 3 of 6Exclusion criteria
Exclusion criteria are (1) severe pain of other origin, e.g.
musculoskeletal pain that in the opinion of the investi-
gator may interfere with the reporting of the neuro-
pathic pain being targeted; (2) metal implants/coils/
electronic devices; (3) drug or alcohol abuse; (4) pregnancy;
(5) psychiatric or psychological disorders; (6) epilepsy; (7)
inability to understand instructions or operate equipment;
(8) high-dose opioids; (9) uncontrolled medical conditions
(e.g. active cancer, uncontrolled renal, pulmonary or cardiac
disease). (As the patients recruited have passed the strin-
gent rTMS study entry criteria, these restrictions are un-
likely to prevent many entering.) Patients were diagnosed
with neuropathic pain, according to the new classification
[38]. Two specialists (neurologist, pain specialist) had to
agree on the diagnosis. Alcohol and drug abuse was ruled
out during the interview and review of medical records.Study design
This study will be a randomised, double-blind, double
cross-over, sham-controlled trial. Three stimulation
modes will be compared: anodal, cathodal and sham
stimulation.
Twelve responders and 12 non-responders to rTMS
will be randomly assigned to receive anodal, cathodal or
sham stimulation as their first treatment session.Randomisation
Randomisation will be done by a research clerk not
otherwise involved in the study. Computer-generated
numbers will be used to create the participant numbers
and order lists. The latter will be placed in a numbered
opaque envelope and sealed. The copy of the order lists
and participant numbers is kept by the research clerk.Initial and follow-up assessments
The initial and follow-up assessments will include a rec-
ord of (1) handedness (not in follow-up assessments); (2)
NRS for pain, including measurements for overall daily
pain severity, unpleasantness of pain and severity of par-
oxysmal pain attacks if present. Pain diaries will be filled
out daily for 1 week at baseline and for 14 days begin-
ning at each stimulation period [39]. (3) Health status
will be assessed by the Short Form 36 Health Survey
(SF-36) [39]. (4) Anxiety and depression will be assessed
by the hospital anxiety and depression scale (HADS)
[40], as well as (5) the mini-mental state examination
[41] and (6) patient experience of equipment use, includ-
ing convenience and adverse effects [39]. Patients are
given contact details of medically qualified personnel to
contact in case of serious side effects. These will be
reported descriptively.Determination of the stimulation site
The stimulation site will be the same as used during pre-
vious TMS treatments. In practice, this will mean pla-
cing the anodal/cathodal electrode over the primary
motor or premotor cortex contralateral to the pain. All
patients have previously had an MRI of the brain and
their localisation on the scalp of the previous TMS treat-
ment can be easily obtained using the brain navigation
system associated with the PRI TMS device (eXimia,
Nextsim, Helsinki, Finland). In the few cases where this
is not possible, the location will be based on bony land-
marks as advised by Fregni et al. [10]. In those cases
where multiple sites were stimulated using TMS, the site
of best response will be chosen.
Direct current will be delivered from a battery-driven,
constant current stimulator (Magstim HDCStim stimula-
tor, The Magstim Co., Whitland, UK) using saline-soaked
surface sponge electrodes (5 × 5 cm) placed over the previ-
ously identified area to target the motor cortex (M1) and
over the contralateral supraorbital area. The device will be
worn for 20 min each day for 5 days consecutively begin-
ning on the first day of their visit. During active treatment
the current delivered will be 1.4 mA with a size 25 cm2
electrode. (Changing the direction of the current will
result in either anodal or cathodal stimulation with the
M1 stimulation being the determinant of which mode is
being used.) All subjects are asked to remain non-active
during this time and engage in either light reading/watch-
ing television or listening to the radio.Sham intervention
For sham stimulation, the electrodes are placed in the
same positions as for anodal M1 stimulation; however, a
constant current of 1.4 mA is only delivered for 30 s
(10-s ramp on). During active tDCS treatment, subjects
typically report tingling sensations under the electrodes,
which rapidly fade [37]. Our sham intervention is there-
fore designed to provide an initial period of tingling so
similar sensations are perceived during active and sham
tDCS protocols. This sham protocol has been used by
previous investigators [22,42]. Data and instructions on
the device display are identical in active and sham set-
tings. Patients will be asked if they can guess the order
of stimulation or if they identify any differences in
stimulation sessions. This guess will be checked against
the actual stimulation order after unblinding.
A research assistant (not otherwise connected with
the study) will set the stimulation characteristics as
indicated by the information in a sealed envelope
opened at the patient visit (anodal/cathodal/sham).
This will be repeated at the two subsequent visits. The
mode of stimulation is not revealed to the patient or
investigators.
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At the first visit subjects are measured up for individually
fitted headband locators for electrode placement. Head-
bands are measured and marked relative to ear tragi, the
nose and midline of scalp. A separate occipital band
ensures the locator headband cannot slip from its position.
Anodal and cathodal electrodes are differently coloured
(red and black) and the patient is shown which way
around they should be placed. Once fitted, subjects are
shown how to position the headbands reproducibly and
instructed on how to position the band markers relative to
the anatomical landmarks described. Patients are then
asked to demonstrate this to the investigator and feedback
given until electrodes are correctly and reproducibly posi-
tioned. Photographs and measurements are taken in case
of the need for reference at home and all instructions are
given to the patient in writing also. In this patient infor-
mation leaflet subjects are informed of potential side
effects such as tingling, burning sensation, dizziness, head-
ache, nausea and phosphenes while switching the device
on or off abruptly. Electrode placement is re-checked at
the beginning of each treatment block.
Programming of devices requires a dedicated program-
mer with security code access. Overriding or manual repro-
gramming is not available to patients.
Study flow
The study will have five phases. At baseline (visit 0, one
of their rTMS treatment visits), the patient is given a
short presentation of how the tDCS device is used with
one of the investigators being the substitute patient. The
patient will then receive the Patient Information Sheet
and Pain diary. If they wish to join the study they will
contact the Research Clerk after having read the infor-
mation after a minimum of 24 h. The Research Clerk
will provide the appointment for visit 1, advising the pa-
tient to fill in the pain diary over a minimum of 7 days.
At visit 1, eligibility will be determined (as per inclusion
and exclusion criteria). Provided they are eligible patients
will be recruited and consented. The patient and carer/
partner will then be shown how to apply the tDCS device,
and the patient will then try it on themselves, with the
help of the carer/partner if necessary. The first trial stimu-
lation will be carried out according to the randomisation
order by the research assistant. The investigators will then
confirm that the patient and carer/partner have under-
stood all details of the stimulation. Following instructions
regarding the daily use of the device, a further pain diary
is supplied and a subsequent visit agreed in 2 weeks’ time.
At this visit (visit 2), the patient will return the pain diary
and will surrender the tDCS device. The third visit (3) will
be arranged for a further 4 weeks’ time (wash-out period);
during the interim a daily pain diary will be kept. At visit
3, the tDCS device will be returned to the patient, and anew stimulation mode will be selected by the research
assistant as per the randomisation order. After 2 weeks
(visit 4), the tDCS device will again be surrendered to the
investigators and the second wash-out period of 4 weeks
with diary keeping started. At visits 5 and 6, tDCS device
will be received and later surrendered by the patient as
during previous treatment arms. The final visit (7) will
happen in a further 2 week’s time.
In the case of patients who wish to continue, the tDCS
device will be given him/her for regular daily use and visits
agreed at 1 month, 3 months, 6 months and 12 months.
Before each visit, they are asked to keep a 1-week pain
diary to assess their mean pain level.
Evaluation of tDCS delivery
Primary and secondary outcome measures
The primary outcome measure will be the mean daily
pain intensity during each mode of tDCS. Secondary
outcome measures will be change in hospital anxiety
and depression scale (HADS), mini mental state examin-
ation and the general health survey (SF 36). Monitoring
of device usage will also be recorded, along with patient
experience of using the device. At the end of each treat-
ment the device will be returned and interrogated to record
actual date, time, duration and number of stimulations
delivered and if stimulations were successful.
Sample size calculations
As this is a pilot study, it is based on an opportune sam-
ple of 24 patients who have previously undergone rTMS
and expressed willingness to take part in the study. No
formal power calculations have therefore been carried
out. If, however, 8/12 responders receiving anodal tDCS
report a beneficial effect [weekly mean reduction of 30%
or 2 units on NRS (0–10) from tDCS] and just 2/12 of
non-responders do the same, this itself would give a stat-
istical significance of p = 0.036 (two-tailed Fisher’s exact
test). Other results would yield important data for future
studies (see below).
Statistical analysis
A linear mixed model will be formed with fixed effects
of mode of tDCS, treatment sequence, responder group
and treatment period, and the random effect as patient
(nested in sequence); the model will be first fitted with
the pain intensity data. All patients will be included and
all pairwise comparisons will be made with the estimated
contrast from this model. Secondary continuous out-
come measures will be analysed in the same way as the
primary endpoint. Baseline covariates will be incorpo-
rated as standard fixed effects but the sensitivity of the
results to other ways of incorporating baseline informa-
tion will be assessed [43]. This information will be used
to inform future studies. Where required, change in pain
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as the difference between pain during run-in baseline
and pain over 3 consecutive weeks following tDCS treat-
ment. Analysis will be performed using Stata software
(StataCorp, Stata Statistical Software, College Station,
TX: StataCorp LP). A proportion analysis will also be
carried out with patients separated into responders and
non-responders and their response rated as positive
(pain reduction from run-in baseline of at least 2 units
on VAS 0–10, or 30%) and negative (pain relief less) and
analysis carried out separately for the three different
tDCS treatments.Discussion
With the effectiveness of non-invasive M1 stimulation
recently demonstrated there has been a call from patients
to facilitate more convenient forms of this therapy. It has
been in direct response to this patient lead call that the
present exploration of home-based non-invasive tDCS of
M1 has been devised. Self-administration of tDCS obvi-
ously has both advantages and disadvantages. While it
may not confer the same accuracy and consistency as
clinic-based, professionally administered stimulation ses-
sions, it does reflect the necessity for patients to be able to
administer this type of therapy in the convenience of their
own home. It is recognised that there will be limitations
on the ability to control timing of stimulus applications
and there may be some variability in technique. However,
all subjects will be thoroughly briefed in the correct posi-
tioning of electrode placement and measurements will be
made against previously taken MRI scans and navigated
TMS data. These measurements are transferred on to
securely locating headbands that are fitted individually to
each patient. Each subject is observed while placing the
electrodes on a number of occasions to ensure correct
technique. The study described is very much a real-world
test of both the effectiveness and practicality of using
tDCS in this patient population, with a method of delivery
that is based on other portable home-use devices such as
transcutaneous electrical nerve stimulation, which has
been in use for several years, albeit with varying success. If
a positive effect is demonstrated it may represent an im-
portant cost-efficient option for non-invasive motor cortex
stimulation in the treatment of chronic pain.Trial status
This trial is on-going and actively enrolling.
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